Showing results (261-270 of 305) with videos related to
Sort By:
Pageof 31
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.Leukemia & Lymphoma|September 3, 2010
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt, Josefina Udi, Martina Kleber, et al.Haematologica|September 2, 2018
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and whenJo Caers, Laurent Garderet, K Martin Kortüm, et al.Haematologica|August 18, 2025
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trialSara Bringhen, Lorenzo Cani, Nicola Giuliani, et al.The Lancet. Oncology|June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma NetworkHeinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.Blood|October 8, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasoneLuca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero, et al.Blood|March 2, 2021
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugsCandida Vitale, Chiara Salvetti, Valentina Griggio, et al.Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.Clinical Lymphoma, Myeloma & Leukemia|April 26, 2025
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) ItalyLorenzo Cani, Maria Teresa Petrucci, Katia Mancuso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.Pageof 31